ARGX

ARGENX SE: 2024 Annual Report (Form 20-F) Summary

Business Context and Reporting Period

Company: ARGENX SE
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: ARGENX is a commercial-stage, global biopharma company focused on severe autoimmune diseases. Its primary commercial products are VYVGART (efgartigimod alfa) and VYVGART SC (efgartigimod alfa + hyaluronidase), approved for generalized myasthenia gravis (gMG), chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenia (ITP). The company operates a deep pipeline including empasiprubart (C2 inhibitor) and ARGX-119 (MuSK agonist).

Key Financial Metrics (Year Ended Dec 31, 2024)

Note: The 2024 net profit includes a significant one-time income tax benefit of $747.9 million, primarily due to the recognition of previously unrecognized deferred tax assets in Belgium ($725 million) based on the company's transition to sustainable profitability.

Material Changes vs. Prior Period

• Revenue Growth: Product net sales nearly doubled, driven by the global commercialization of VYVGART and VYVGART SC for gMG and the new launch of VYVGART HYTRULO for CIDP in the U.S., China, and Japan.
• Profitability Transition: The company recorded its first annual net profit ($833 million) compared to a net loss of $295 million in 2023. This was largely driven by the recognition of deferred tax assets, though operating performance also improved significantly with the operating loss narrowing from $425 million to $22 million.
• Expense Increases: R&D expenses rose 14% due to the advancement of the pipeline (empasiprubart, ARGX-119) and expansion of efgartigimod into new indications. SG&A expenses increased 48% due to scaling commercial operations and marketing efforts.
• Foreign Exchange: The company reported an exchange loss of $48.2 million in 2024, compared to a gain of $14.1 million in 2023, primarily due to the strengthening of the Euro against the USD.

Guidance, Outlook, and Management Commentary

• Vision 2030: Management outlined a long-term strategy to treat 50,000 patients globally, secure 10 labeled indications, and advance five pipeline candidates into Phase 3 by 2030.
• Commercial Outlook: The company expects continued growth in gMG and CIDP. Key upcoming milestones include the PDUFA date for the pre-filled syringe (PFS) formulation in the U.S. (April 10, 2025) and expected approvals for VYVGART SC for CIDP in the EU in 2025.
• Pipeline Progress:
  • efgartigimod: Phase 3 trials ongoing for Myositis (ALKIVIA), Primary Sjögren's disease (UNITY), and Thyroid Eye Disease (UplighTED). "Go" decisions made for Myositis and Sjögren's.
  • empasiprubart: Advanced to Phase 3 for Multifocal Motor Neuropathy (MMN) following positive Phase 2 data. Phase 3 for CIDP expected to start in 2025.
  • ARGX-119: Proof-of-concept studies initiated for Congenital Myasthenic Syndrome (CMS) and ALS.
• Liquidity: Management stated that existing cash, cash equivalents, and current financial assets ($3.4 billion combined) are sufficient to fund operations and capital expenditures for at least the next 12 months.

Risks and Contingencies

• Regulatory and Pricing: Risks include potential changes in U.S. healthcare legislation (Inflation Reduction Act) affecting pricing and reimbursement, as well as ongoing pricing negotiations in the EU and other jurisdictions.
• Competition: Intense competition in the autoimmune space, including potential biosimilar competition for VYVGART (though exclusivity extends to 2033 in the U.S. and 2032/2033 in the EU/UK).
• Manufacturing: Reliance on third-party contract manufacturers (e.g., Lonza, Fujifilm) creates supply chain risks.
• Deferred Tax Assets: The 2024 profit is heavily influenced by the recognition of deferred tax assets. Future profitability depends on the realization of these assets against future taxable income.

Key Facts for Investor Verification

• Deferred Tax Recognition: Verify the sustainability of the $725 million deferred tax asset recognition in Belgium and the assumptions regarding future taxable profits used to justify this.
• Revenue Concentration: Confirm the concentration of revenue, as five U.S. customers represented approximately 87% of product net sales in 2024.
• Pipeline Milestones: Monitor the upcoming PDUFA date for the VYVGART PFS (April 2025) and the initiation of Phase 3 trials for empasiprubart in CIDP.
• Cash Position: Track the utilization of the $3.4 billion in liquid assets (cash + current financial assets) against the increasing burn rate from R&D and commercial expansion.
• Foreign Exchange Exposure: Assess the impact of EUR/USD fluctuations on future earnings, given the significant Euro-denominated cash and asset positions.